Navigation Links
ViveBio, LLC Enters Worldwide Exclusive Licensing Agreement with Renovar Inc. for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
Date:2/10/2015

ALPHARETTA, Ga., Feb. 10, 2015 /PRNewswire/ -- ViveBio, LLC announced today that it has signed a worldwide exclusive licensing agreement with Renovar, Inc. for urine based biomarkers to predict and monitor kidney diseases as well as rejection in transplant recipients.  Based upon unique inflammatory protein signatures found in the urine of diseased or injured kidney's, the Renovar technology can be used to assess the health of a patients kidney's, guide therapeutic decision making and help stratify patients by risk for developing acute rejection. 

"This is an important step for ViveBio as the company evolves from a purely preanalytical player into a clinical diagnostics business," said Timothy Murray, ViveBio President.  "This technology enables monitoring of kidney transplant patients for the earliest indication of rejection and will give clinicians a new tool in post transplant patient management." Current medical practice assesses the health of the implanted kidney by monitoring and measuring non-specific signals within the body (i.e. serum creatinine) and unfortunately, these signals can only be measured after the process of rejection has started and kidney damage has occurred.

Based upon an NIH sponsored, prospective, multicenter study of 280 kidney transplant recipients researchers evaluated the urinary levels of nine messenger RNAs and two proteins which are known to be associated with kidney transplant rejection.  They identified Monokine induced by interferon-gamma (MIG) messenger RNA (mRNA) and MIG protein as the clinically significant biomarkers.  After further testing, the researchers found that MIG protein was better at ruling out rejection than any of the mRNA's tested.  It was also capable of identifying patients likely to have stable long-term kidney function and identify those patients who were unlikely to experience rejection or loss of kidney function over the next 18 months.  The investigators noted that urinary MIG protein levels began to increase up to 30 days before clinical signs of kidney injury.

In an NIH issued press release, NIAID Director Dr. Anthony S. Fauci, M.D. said, "A noninvasive urine test to accurately monitor the risk of kidney rejection could dramatically reduce the need for biopsies and possibly enable doctors to safely reduce immunosuppressive therapy in some patients. . ." Dr. Fauci went on to say, "The results of this study support the further development of noninvasive tests for the detection and management of transplant rejection."

"It's exciting to see this technology moving forward which can potentially help kidney transplant patients avoid problems and enjoy longer function from their new kidney," said Dr. Stuart Knechtle, M.D., F.A.C.S.  Executive Director, Duke University Transplant Center.

"We plan to make a urine based MIG protein assay available in 2016 either through a CLIA laboratory or one of the platforms we are evaluating," said Murray.  "ViveBio is preparing for additional clinical studies as well as exploring collaborations with pharmaceutical companies to employ the MIG protein test and other biomarkers as companion diagnostics in the Transplant and Kidney Disease areas."

About ViveBio, LLC   

ViveBio, LLC is a privately held biotechnology company focused on providing high quality yet cost-effective solutions for specimen transportation, storage and blood component separation, along with cutting edge clinical diagnostics.  ViveBio's mission is to expand access to healthcare and extend life through these cost effective solutions and other breakthrough technologies.  The company's manufacturing and corporate office are located in Alpharetta, Georgia.  For more information regarding ViveST and recent scientific publications and posters, please visit the ViveBio website at http://www.vivebio.com/about-us

About Renovar, Inc.

Renovar, founded in 1999 by an internationally-recognized University of Wisconsin-Madison transplant surgeon, is an early-stage biotechnology company pioneering the development of diagnostic tests for kidney disease and transplant monitoring. The company's portfolio of patented Kidney-disease biomarkers coupled with its proprietary urine buffer system, which permits assaying of urine not possible otherwise, enable the potential for non-invasive, timelier detection with greater sensitivity and specificity.

ViveBio, LLC
Corporate Contact:
Tim Murray, President

or

Brad Nelson
Investor Relations
1-877-814-7004
nelson@vivebio.com

Renovar, Inc.
Corporate Contact:
Charlie Goff
Investor Relations
1-920-731-5777


'/>"/>
SOURCE ViveBio, LLC
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Endexx Enters Into Definitive Agreement to Acquire Dispense Labs, LLC
2. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
3. Neurelis Enters into Option and Merger Agreement with Biotie Therapies
4. A Finnish Company Enters International Markets With World Class Genetics Technology
5. U.S. News & World Report Honors 7 SynCardia Certified Centers Among "Best Childrens Hospitals" for Cardiology and Heart Surgery
6. Queen Emma Land Company and Taubman Centers Announce Saks Fifth Avenue to Anchor the Revitalized International Market Place
7. Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities
8. Parent Project Muscular Dystrophy Returns to Baltimore for Annual Connect Conference; Presenters Include FDA, Major Pharma
9. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
10. Odense Universitetshospital tilfører kræftpatienters stereotaktiske strålebehandling næsten tre gange hurtigere med Elektas Versa HD-system
11. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2019)... ... 15, 2019 , ... Mold doesn’t need things to be wet in order ... detectable to the eye or by touch. ServPro in Cayucos , the mold ... explaining the conditions that mold needs to grow and how to prevent those conditions. ...
(Date:11/14/2019)... ... 2019 , ... Researchers at Worcester Polytechnic Institute (WPI) are ... blood oxygen levels, a vital indication of the lungs’ effectiveness and whether the ... this miniaturized wearable device will be flexible and stretchable, wireless, inexpensive, and mobile—possibly ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... K-FISH, aimed to promote the quality of Korean seafood and enhance its global ... entitled, "K-Seafood Global Weeks" in many countries. These special events are currently ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... November 11, 2019 , ... Early praise for A ... down the complexities of scholarly writing and provides key insight and vital guidance for ... DNP Project will have a permanent place on my bookshelf and will be shared ...
(Date:11/11/2019)... Calif. (PRWEB) , ... November 11, 2019 , ... ... of business support services to dental groups in the United States, today announced ... the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable offices ...
(Date:11/11/2019)... LAS VEGAS (PRWEB) , ... November 11, 2019 , ... ... buyers from 46 different countries including big box buyers like Costco, Walmart, and GNC. ... CBDfx, and GRN to name a few. , This year, CBD.io ...
(Date:11/11/2019)... ... November 11, 2019 , ... Artemis, ... prevention and urges increased adoption of compliance technology in the wake of the ... sold to select retailers in the United States and Canada due to potential ...
(Date:11/11/2019)... ... 11, 2019 , ... PracticeLink Live! Atlanta Physician Career Fair will take place ... 5:00 p.m. and continue until 8:00 p.m. A free, optional seminar for job-seeking physicians, ... 6:30 p.m. , Both the career fair and seminar are open to residents and ...
Breaking Medicine News(10 mins):